Home |  English version |  Mappa |  Commenti |  Sondaggio |  Staff |  Contattaci Cerca nel sito  
Istituto di scienza dell'alimentazione

Torna all'elenco Contributi in rivista anno 2010

Contributo in rivista

Tipo: Articolo in rivista

Titolo: In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder

Anno di pubblicazione: 2010

Formato: Elettronico Cartaceo

Autori: Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F, De Laurentiis A, Luberto L, Pontoriero M, Pisano A, Vecchio E, Fierro O, Panico MR, Larobina M, Gargiulo S, Costa N, Dal Piaz F, Schiavone M, Arra C, Giudice A, Palma G, Barbieri A, Qui

Affiliazioni autori: Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia," Catanzaro; Italsistemi Biotechnology Institute, Crotone; Department of Experimental Oncology, National Cancer Institute INT, Foundation G. Pascale, Naples; Institute of Food Sciences National Research Council, Avellino; Institute of Biostructure and Bioimaging, National Research Council, Naples; Department of Functional and Biomorphologic Sciences--CEINGE- University Medical School of Naples "Federico II," Naples; Department of Pharmaceutical Sciences, University of Salerno, Salerno; Department of Biochemistry and Medical Biotechnology, University Medical School of Naples "Federico II," Naples, Italy

Autori CNR:

  • OLGA FIERRO
  • SARA GARGIULO
  • MICHELE LAROBINA
  • MARIAROSARIA PANICO

Lingua: inglese

Abstract: B-cell lymphoma is a clonal expansion of neoplastic cells that may result in fatal outcomes. Here, we report the in vivo targeting and growth inhibition of aggressive A20 murine B-cell lymphoma by idiotype-specific peptide pA20-36. pA20-36 was selected from random peptide libraries and bound specifically to the B-cell receptor (BCR) of A20 cells in mice engrafted with A20 lymphoma, as shown by histology and positron emission tomographic analysis. BCR cross-linking of A20 cells with pA20-36 resulted in massive apoptosis of targeted tumor cells and in an increased survival of the diseased animals without any detectable evidence of toxicity. The pA20-36 treatment reverted the immune suppression of the tumor microenvironment as shown by reduced expression of vascular endothelial growth factor, interleukin-10, and transforming growth factor-beta cytokines together with a lower number of CD11b+Gr-1+ inhibitor myeloid-derived suppressor cells and Foxp3+CD4+ Treg cells. Furthermore, pA20-36 treatment was associated with an increased number of tumor-infiltrating, activated CD8+ T cells that exerted a tumor-specific cytolytic activity. These findings show that a short peptide that binds specifically to the complementarity-determining regions of the A20 BCR allows in vivo detection of neoplastic cells together with significant inhibition of tumor growth in vivo.

Lingua abstract: inglese

Pagine da: 226

Pagine a: 238

Rivista:

Blood W.B. Saunders Co., etc.]
Paese di pubblicazione: Stati Uniti d'America
Lingua: inglese
ISSN: 0006-4971

Numero volume: 116

DOI: 10.1182/blood-2009-11-253617

Indicizzato da: ISI Web of Science (WOS) [000279955800013]

Strutture CNR:

Moduli:

 
Torna indietro Richiedi modifiche Invia per email Stampa
Home Il CNR  |  I servizi News |   Eventi | Istituti |  Focus